Drug intelligence / Profile preview

HCR040

Development stage: Unknown
Lead developer: Histocell
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

HCR040 is an allogeneic cell therapy developed by Histocell, consisting of adipose-derived adult mesenchymal stem cells (MSCs) designated as HC016. These cells are expanded and pulsed with hydrogen peroxide (H2O2) during the manufacturing process to enhance their resistance to oxidative stress and boost their immunomodulatory properties. This priming is intended to improve cell survival and therapeutic efficacy when administered into the highly inflammatory and oxidative environment characteristic of Acute Respiratory Distress Syndrome (ARDS). HCR040 aims to reduce pulmonary inflammation and promote tissue repair in patients suffering from severe respiratory failure.

Other names: HC016HC-016HC 016adipose derived mesenchymal stromal cellsallogeneic adipose-derived adult mesenchymal stem cells

Beyond the preview

Go deeper on HCR040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCR040.

Explore the full profile